Skip to main content

SYSTEMATIC REVIEW article

Front. Cardiovasc. Med.
Sec. Cardiovascular Epidemiology and Prevention
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1453297

Comparison of glucagon-like peptide-1 receptor agonists vs placebo on any cardiovascular events in overweight or obese non-diabetic patients: A systematic review and meta-analysis

Provisionally accepted
Raveena Kelkar Raveena Kelkar 1*Nishad A. Barve Nishad A. Barve 2Rohan Kelkar Rohan Kelkar 3Sanjeev Kharel Sanjeev Kharel 4Shalmi Khanapurkar Shalmi Khanapurkar 5Rukesh Yadav Rukesh Yadav 4
  • 1 Cleveland Clinic Akron General, Akron, United States
  • 2 Cleveland Clinic Mercy Hospital, Canton, United States
  • 3 Sahyadri Hospitals, Pune, Maharashtra, India
  • 4 Maharajgunj Medical Campus, Institute of Medicine, Kathmandu, Nepal
  • 5 Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India

The final, formatted version of the article will be published soon.

    Glucagon-like peptide 1 receptor agonists (GLP-1 RA) have been extensively used to treat obesity in recent years. These novel drugs are effective at reducing body weight and also the risk of major adverse cardiovascular events in individuals with type 2 diabetes. However, the data of its efficacy in reducing cardiovascular events in individuals without type 2 diabetes is not as robust. We aim to update and conduct a systematic review and meta-analysis to assess the same.The study was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guideline. Researchers searched PubMed, EMBASE, and Clinicaltrails.gov for English literature from inception to 2024. Randomized Controlled trails enrolling adult participants (age ≥ 18 years) who are overweight or obese (BMI>25 Kg/m 2 ) with a comparison of all cardiovascular events between patients taking GLP1-RA and placebo were included. The analysis was done by Revman version 5.4.A total of 17 RCTs among 34,419 participants were included in the analysis. The pooled risk ratio from 17 studies illustrated that patients with GLP-1 RA had a significantly lower risk of cardiovascular events compared to patients who had a placebo (RR=0.75; 95% confidence interval 0.64 to 0.89, p-value=0.0008). Semaglutide was found to have a statistically significant greatest risk reduction than other drug types.This meta-analysis found that GLP-1 RA significantly reduced all types of cardiovascular events in overweight and obese patients without diabetes. Semaglutide was found to be superior to others in CV event reductions. But still, the results of ongoing trials are needed.

    Keywords: GLP-1 RA, Obesity, Cardiovascular event, Non-diabetic, Overweight

    Received: 19 Jul 2024; Accepted: 21 Aug 2024.

    Copyright: © 2024 Kelkar, Barve, Kelkar, Kharel, Khanapurkar and Yadav. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Raveena Kelkar, Cleveland Clinic Akron General, Akron, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.